Prospects for the combined use of trans-resveratrol and indole-3-carbinol in endometriosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Endometriosis is considered to be a multifactorial disease, the prevalence of which does not tend to decrease, including in reproductive-aged women, with a delay in diagnosis ranging from 4 to 11 years. A number of disadvantages and side effects of the existing treatments, both surgical and medical, as well as the importance of long-term therapy for the disease justify the need to search for new approaches to drug treatment, both for combined use with known drugs, and as monotherapy. Based on the Russian and foreign literature sources of the electronic databases PubMed, CyberLeninka, and Google Scholar in the period from 2003 to 2021, as well as the results of the authors’ own studies, the review presents an update on the use of trans-resveratrol and indole-3-carbinol in external genital endometriosis and adenomyosis both in experimental models and in clinical practice. The pharmacological effects of compounds, (antioxidant, anti-inflammatory, antimicrobial, neuroprotective, anticarcinogenic, and others) determine the prospects for the combined use of trans-resveratrol and indole-3-carbinol in the treatment of various forms of genital endometriosis. Conclusion: Further investigation is needed to adjust the most effective dosage regimens for the combination use of indole-3-carbinol 200 mg and trans-resveratrol 60 mg in patients with endometriosis and adenomyosis.

Full Text

Restricted Access

About the authors

Maria I. Yarmolinskaya

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology; North-Western State Medical University named after I.I. Mechnikov

Email: m.yarmolinskaya@gmail.com
Professor of Russian Academy of Sciences, Dr. Med. Sci., Professor, Head of the Department of Gynecology and Endocrinology, Head of the Center "Diagnostics and treatment of endometriosis”

Maria A. Shalina

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology

Email: amarus@inbox.ru
PhD, Senior Researcher at the Department Gynecology and Endocrinology

Aleksandra K. Beganova

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology

Email: alexandra.beganova@yandex.ru
Junior Researcher

Chimnaz I. kyzy Seyidova

D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology

Email: seidov_46@mail.ru
Resident Physician

References

  1. Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020; 382(13): 1244-56. https://dx.doi.org/10.1056/NEJMra181076.
  2. Agarwal S.K., Chapron C., Giudice L.C., Laufer M.R., Leyland N., Missmer S.A. et al. Clinical diagnosis of endometriosis: a call to action. Am. J. Obstet. Gynecol. 2019; 220(4): 354.e1-354.e12. https://dx.doi.org/10.1016/j.ajog.2018.12.039.
  3. Ярмолинская М.И., ред. Медикаментозная терапия генитального эндометриоза: реалии и перспективы. Руководство для врачей. М.: ГЭОТАР-Медиа; 2021. 384 с. [Yarmolinskaya M.I., ed. Pharmacological treatment of endometriosis: realities and prospects: guide for doctors. Moscow: GEOTAR-Media; 2021. 384 p. (in Russian)]. https://dx.doi.org/10.33029/9704-6034-4-MET-2021-1-384.
  4. Samimi M., Pourhanifeh M., Mehdizadehkashi A., Eftekhar T., Asemi Z. The role of inflammation, oxidative stress, angiogenesis, and apoptosis in the pathophysiology of endometriosis: Basic science and new insights based on gene expression. J. Cell. Physiol. 2019; 234(11): 19384-192. https://dx.doi.org/10.1002/jcp.28666.
  5. Donnez J., Dolmans M.M. Endometriosis and medical therapy: From progestogens to progesterone resistance to GnRH antagonists: A review. J. Clin. Med. 2021; 10(5): 1085. https://dx.doi.org/10.3390/jcm10051085.
  6. Fiod Riccio B.V., Fonseca-Santos B., Colerato Ferrari P., Chorilli M. Characteristics, biological properties and analytical methods of trans-resveratrol: A review. Crit. Rev. Anal. Chem. 2020; 50(4): 339-58. https://dx.doi.org/10.1080/10408347.2019.1637242.
  7. Shaito A., Posadino A.M., Youne, N., Hasan H., Halabi S., Alhababi D. et al. Potential adverse effects of resveratrol: A literature review. Int. J. Mol. Sci. 2020; 21(6): 2084. https://dx.doi.org/10.3390/ijms21062084.
  8. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nature reviews. Drug Discov. 2006; 5(6): 493-506. https://dx.doi.org/10.1038/nrd2060.
  9. Patel K.R., Andreadi C., Britton R.G., Horner-Glister E., Karmokar A., Sale S. et al. Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013; 5(205): 205ra133. https://dx.doi.org/10.1126/scitranslmed.3005870.
  10. Britton R.G., Kovoor C., Brown K. Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann. N. Y. Acad. Sci. 2015; 1348(1): 124-33. https://dx.doi.org/10.1111/nyas.12796.
  11. Iside C., Scafuro M., Nebbioso A., Altucci L. SIRT1 Activation by natural phytochemicals: An overview. Front. Pharmacol. 2020; 11: 1225. https://dx.doi.org/10.3389/fphar.2020.01225.
  12. Nakayama H., Yaguchi T., Yoshiya S., Nishizaki T. Resveratrol induces apoptosis MH7A human rheumatoid arthritis synovial cells in a sirtuin 1-dependent manner. Rheumatol. Int. 2012; 32(1): 151-7. https://dx.doi.org/10.1007/s00296-010-1598-8.
  13. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B. et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012; 15(5): 675-90. https://dx.doi.org/10.1016/j.cmet.2012.04.003.
  14. Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K. et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010; 299(1): H18-H24. https://dx.doi.org/10.1152/ajpheart.00260.2010.
  15. Pyo I.S., Yun S., Yoon Y.E., Choi J.W., Lee S.J. Mechanisms of aging and the preventive effects of resveratrol on age-related diseases. Molecules. 2020; 25(20): 4649. https://dx.doi.org/10.3390/molecules25204649.
  16. Rabinovitch R.C., Samborska B., Faubert B., Ma E.H., Gravel S.P., Andrzejewski S. et al. AMPK maintains cellular metabolic homeostasis through regulation of mitochondrial reactive oxygen species. Cell Rep. 2017; 21(1): 1-9. https://dx.doi.org/10.1016/j.celrep.2017.09.026.
  17. Widlund A.L., Baur J.A., Vang O. mTOR: more targets of resveratrol? Expert Rev Mol. Med. 2013; 15: e10. https://dx.doi.org/10.1017/erm.2013.11.
  18. Devis-Jauregui L., Eritja N., Davis M.L., Matias-Guiu X., Llobet-Navas D. Autophagy in the physiological endometrium and cancer. Autophagy. 2021; 17(5): 1077-95. https://dx.doi.org/10.1080/15548627.2020.1752548.
  19. Ashrafizadeh M., Taeb S., Haghi-Aminjan H., Afrashi S., Moloudi K., Musa A.E. et al. Resveratrol as an enhancer of apoptosis in cancer: a mechanistic review. Anticancer Agents Med. Chem. 2021; 21(17): 2327-36. https://dx.doi.org/10.2174/1871520620666201020160348.
  20. Saqib U., Kelley T.T., Panguluri S.K., Liu D., Savai R., Baig M. et al. Polypharmacology or promiscuity? Structural interactions of resveratrol with its bandwagon of targets. Front. Pharmacol. 2018; 9: 1201. https://dx.doi.org/10.3389/fphar.2018.01201.
  21. Qasem R.J. The estrogenic activity of resveratrol: a comprehensive review of in vitro and in vivo evidence and the potential for endocrine disruption. Crit. Rev. Toxicol. 2020; 50(5): 439-62.https://dx.doi.org/10.1080/10408444.2020.1762538.
  22. Bhat K.P., Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Ann. N. Y. Acad. Sci. 2002; 957: 210-29. https://dx.doi.org/10.1111/j.1749-6632.2002.tb02918.x.
  23. Amaya S.C., Savaris R.F., Filipovic C.J., Wise J.D., Hestermann E., Young S.L. et al. Resveratrol and endometrium: a closer look at an active ingredient of red wine using in vivo and in vitro models. Reprod. Sci. 2014; 21(11): 1362-9. https://dx.doi.org/10.1177/1933719114525271.
  24. Li H., Xia N., Hasselwander S., Daiber A. Resveratrol and vascular function. Int. J. Mol. Sci. 2019; 20(9): 2155. https://dx.doi.org/10.3390/ijms20092155.
  25. Chen Y., Tseng S.H. Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo. 2007; 21(2): 365-70.
  26. Ogas T., Kondratyuk T.P., Pezzuto J.M. Resveratrol analogs: promising chemopreventive agents. Ann. N.Y. Acad. Sci. 2013; 1290: 21-9. https://dx.doi.org/10.1111/nyas.12196.
  27. Pasquariello R., Verdile N., Brevini T., Gandolfi F., Boiti C., Zerani M. et al. The role of resveratrol in mammalian reproduction. Molecules. 2020; 25(19): 4554. https://dx.doi.org/10.3390/molecules25194554.
  28. Katz E., Nisani S., Chamovitz D.A. Indole-3-carbinol: a plant hormone combatting cancer. F1000Research. 2018; 7: F1000 Faculty Rev-689. https://dx.doi.org/10.12688/f1000research.14127.1.
  29. Aggarwal B.B., Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle. 2005; 4(9): 1201-15. https://dx.doi.org/10.4161/cc.4.9.1993.
  30. Rauf A., Imran M., Butt M.S., Nadeem M., Peters D.G., Mubarak M.S. Resveratrol as an anti-cancer agent: A review. Crit. Rev. Food Sci. Nutr. 2018; 58(9): 1428-47. https://dx.doi.org/10.1080/10408398.2016.1263597.
  31. Bhardwaj A., Sethi G., Vadhan-Raj S. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through downregulation of STAT3 and nuclear factor-kappaB regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109: 2293-302. https://dx.doi.org/10.1182/blood-2006-02-003988.
  32. Ulrich U., Buchweitz O., Greb R., Keckstein J., von Leff ern I., Oppelt P. et al. National German Guideline (S2k): guideline for the diagnosis and treatment of endometriosis. Geburtshilfe Frauenheilkd. 2014; 74(12): 1104-18. https://dx.doi.org/10.1055/s-0034-1383187.
  33. Park E.J., Pezzuto J.M. The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta. 2015; 1852(6): 1071-113. https://dx.doi.org/10.1016/j.bbadis.2015.01.014.
  34. Bruner-Tran K.L., Osteen K.G., Taylor H.S., Sokalska A., Haines K., Duleba A.J. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol. Reprod. 2011; 84(1): 106-12. https://dx.doi.org/10.1095/biolreprod.110.086744.
  35. Ricci A.G., Olivares C.N., Bilotas M.A., Baston J.I., Singla J.J., Meresman G.F. et al. Natural therapies assessment for the treatment of endometriosis. Hum. Reprod. 2013; 28(1): 178-88. https://dx.doi.org/10.1093/humrep/des369.
  36. Cenksoy P.O., Oktem M., Erdem O., Karakaya C., Cenksoy C., Erdem A. et al. A potential novel treatment strategy: Inhibition of angiogenesis and inflammation by resveratrol for regression of endometriosis in an experimental rat model. Gynecol. Endocrinol. 2015; 31(3): 219-24. https://dx.doi.org/10.3109/09513590.2014.976197.
  37. Tekin B.Y., Guven S., Kirbas A., Kalkan Y., Tumkaya L., Guvendag Guven E.S. Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis? Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 184: 1-6. https://dx.doi.org/10.1016/j.ejogrb.2014.10.041.
  38. Chen Z.H., Hurh Y.J., Na H.K. Resveratrol inhibits TCDD induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis. 2004; 25(10): 2005-13. https://dx.doi.org/10.1093/carcin/bgh183.
  39. Ярмолинская М.И., Айламазян Э.К. Генитальный эндометриоз. Различные грани проблемы. СПб.: Эко-Вектор; 2017. 615с.
  40. Chen Z., Wang C., Lin C., Zhang L., Zheng H., Zhou Y. et al. Lipidomic alterations and PPARa activation induced by resveratrol lead to reduction in lesion size in endometriosis models. Oxid. Med. Cell. Longev. 2021; 2021: 9979953. https://dx.doi.org/10.1155/2021/9979953.
  41. Khazaei M.R., Rashidi Z., Chobsaz F., Niromand E., Khazaei M. Inhibitory effect of resveratrol on the growth and angiogenesis of human endometrial tissue in an In Vitro three-dimensional model of endometriosis. Reprod. Biol. 2020; 20(4): 484-90. https://dx.doi.org/10.1016/j.repbio.2020.07.012.
  42. Maia H., Jr, Haddad C., Pinheiro N., Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int. J. Womens Health. 2012; 4: 543-9. https://dx.doi.org/10.2147/ IJWH.S36825.
  43. Mendes da Silva D., Gross L.A., De Paula Guedes Neto E., Lessey B.A., Francalacci Savaris R. The use of resveratrol as an adjuvant treatment of pain in endometriosis: a randomized clinical trial. J. Endocr. Soc. 2017; 1(4): 359-69. https://dx.doi.org/10.1210/js.2017-00053.
  44. Dull A.M., Moga M.A., Dimienescu O. G., Sechel G., Burtea V., Anastasiu C. V. Therapeutic approaches of resveratrol on endometriosis via antiinflammatory and anti-angiogenic pathways. Molecules. 2019; 24(4): 667. https://dx.doi.org/10.3390/molecules24040667.
  45. Киселев В.И., Ашрафян Л.А., Пронин С.М., Герфанова Е.В., Кузнецов И.Н., Друх В.М., Удут В.В., Чурин А.А., Пчелинцева О.И. Изучение эффективности индол-3-карбинола на модели эндометриоза у крыс (экспериментальное исследование). Акушерство и гинекология. 2020; 5: 122-30. [Kiselev V.I., Ashrafyan L.A., Pronin S.M., Gefranova E.V., Kuznetsov I.N., Drukh V.M. et al. Investigation of the efficacy of indole-3-carbinol on a rat model of endometriosis (experimental study). Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 5: 122-30. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.5.122-30.
  46. Ampofo E., Schmitt B.M., Menger M.D., Laschke M.W. Targeting the Microcirculation by indole-3-carbinol and its main derivate 3,3,’-diindolylmethane: effects on angiogenesis, thrombosis and inflammation. Mini Rev. Med. Chem. 2018; 18(11): 962-8. https://dx.doi.org/10.2174/1389557518666180313100144.
  47. Хашукоева А.З., Хлынова С.А., Ильина И.Ю., Керчелаева С.А. Эстрогензависимые состояния женской репродуктивной системы: возможности негормональной терапии с применением индол-3-кар-бинола. Акушерство и гинекология. 2020; 5: 65-9. [Khashukoeva A.Z., Khlynova S.A., Ilyina I.Yu., Kerchelaeva S.A. Estrogen-dependent conditions of the female reproductive system: possibilities of nonhormonal therapy using indole-3-carbinol. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 5: 65-9. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.5.65-69.
  48. Hodler J., Kubik-Huch R.A., von Schulthess G.K., eds. Diseases of the abdomen and pelvis 2018-2021: diagnostic imaging. IDKD Book. Springer; 2018. https://dx.doi.org/10.1007/978-3-319-75019-4.
  49. Upson K., Missmer S.A. Epidemiology of adenomyosis. Semin. Reprod. Med. 2020; 38(2-3): 89-107. https://dx.doi.org/10.1055/s-0040-1718920.
  50. Vannuccini S., Tosti C., Carmona F., Huang S.J., Chapron C., Guo S.W. et al. Pathogenesis of adenomyosis: an update on molecular mechanisms. Reprod. Biomed. Online. 2017; 35(5): 592-601. https://dx.doi.org/10.1016/j.rbmo.2017.06.016.
  51. Давыдов А.И., Пашков В.М., Шахламова М.Н. Субмукозная миома матки в сочетании с аденомиозом. Принципы таргетной терапии в репродуктивном периоде. Вопросы гинекологии, акушерства и перинатологии. 2019; 18(3): 124-32. [Davydov A.I., Pashkov V.M., Shakhlamova M.N. Submucosal leiomyoma of the uterus in combination with adenomyosis. Principles of target therapy in the reproductive period. Voprosy ginekologii, akuserstva i perinatologii/ Issues of Gynecology, Obstetrics and Perinatology. 2019;18(3):124-32. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2019-3-124-132.
  52. Ярмолинская М.И., Шалина М.А., Хачатурян А.Р., Нетреба Е.А., Флорова М.С., Мехтиханова С.В. Аденомиоз: от научных открытий к практическим аспектам назначения медикаментозной терапии. Акушерство и гинекология. 2020; 3: 182-90. [Yarmolinskaya Y.I., Shalina M.A., Khachaturyan A.R., Netreba E.A., Florova M.S., Mekhtikhanova S.V. Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 3: 182-90. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.3.182-190.
  53. Pontis A., DAlterio M.N., Pirarba S., de Angelis C., Tinelli R., Angioni S. Adenomyosis: a systematic review of medical treatment. Gynecol. Endocrinol. 2016; 32(9): 696-700. https://dx.doi.org/10.1080/09513590.2016.1197200.
  54. Gordon S.C. Toxicological evaluation of ammonium 4,8-dioxa-3H-perfluorononanoate, a new emulsifier to replace ammonium perfluorooctanoate in fluoropolymer manufacturing. Regul. Toxicol. Pharmacol. 2011; 59(1): 64-80. https://dx.doi.org/10.1016/j.yrtph.2010.09.00821.
  55. Mariadason J.M., Bordonaro M., Aslam F., Shi L., Kuraguchi M., Velcich A. et al. Down-regulation of P-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res. 2001; 61(8): 3465-71.
  56. Oh S.J., Shin J.H., Kim T.H., Lee H.S., Yoo J.Y., Ahn J.Y. et al. P-Catenin activation contributes to the pathogenesis of adenomyosis through epithelial-mesenchymal transition. J. Pathol. 2013; 231(2): 210-22. https://dx.doi.org/10.1002/path.4224.
  57. Chen Y.J., Li H.Y., Huang C.H., Twu N.F., Yen M.S., Wang P.H. et al. Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. J. Pathol. 2010; 222(3): 261-70. https://dx.doi.org/10.1002/path.2761.
  58. Novakovic R., Ilic B., Beleslin-Cokic B., Radunovic N., Heinle H., Scepanovic R., Gojkovic-Bukarica L. The effect of resveratrol on contractility of non-pregnant rat uterus: the contribution of K(+) channels. J. Physiol. Pharmacol. 2014; 64(6): 795-805.
  59. Carreiro J.N., Magnani M., Jobling P., van Helden D.F., Nalivaiko E., Braga V.A. Resveratrol restores uterine contractions during hypoxia by blockade of ATP-sensitive potassium channels. J. Functional Foods. 2017; 33: 307-13. https://dx.doi.org/10.1016/j.jff.2017.04.001.
  60. Zhu B., Chen Y., Zhang H., Liu X., Guo S.W. Resveratrol reduces myometrial infiltration, uterine hyperactivity, and stress levels and alleviates generalized hyperalgesia in mice with induced adenomyosis. Reprod. Sci. 2015; 22(11): 1336-49. https://dx.doi.org/10.1177/1933719115572479.
  61. Ярмолинская М.И., Шалина М.А., Нетреба Е.А., Милютина Ю.П., Траль Т.Г. Создание экспериментальной модели аденомиоза на крысах линии Wistar. Патент на изобретение RU 2761754 С1. 2021.
  62. Xu W., Song Y., Li K., Zhang B., Zhu X. Quercetin inhibits adenomyosis by attenuating cell proliferation, migration and invasion of ectopic endometrial stromal cells. Drug Des. Devel. Ther. 2020; 14: 3815-26. https://dx.doi.org/10.2147/DDDT.S265066.
  63. Давыдов А.И., Чилова Р.А., Лебедев В.А., Таирова М.Б. Аденомиоз и оксидативный стресс. Обоснование комплексного подхода к лечению пациенток репродуктивного возраста. Вопросы гинекологии, акушерства и перинатологии. 2021; 20(6): 155-61. [Davydov A.I., Chilova R.A., Lebedev V.A., Tairova M.B. Adenomyosis and oxidative stress. Rationale for comprehensive approach to treatment of patients of reproductive age. Voprosy ginekologii, akuserstva i perinatologii/ Issues of Gynecology, Obstetrics and Perinatology. 2021; 20(6): 155-61. (in Russian)]. https://dx.doi.org/10.20953/1726-1678-2021-6-155-61.
  64. Карахалис Л.Ю., Федорович О.К., Васина И.Б., Червонная И.Ю. Влияние патогенетически обоснованной терапии аденомиоза на его течение. Эффективная фармакотерапия. 2009: 5: 18-24.
  65. Оразов М.Р., Чайка А.В., Носенко Е.Н. Возможности негормонального патогенетического лечения хронической тазовой боли у женщин с аденомиозом. Медико-социальные проблемы семьи. 2003: 18(1): 33-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies